Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 18/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294568 | 0.88 | AURKA (0.56) | AURKAAURKBRIPK1 | |
| SCHEMBL10312152 | 0.86 | PAK1 (0.50) | AURKAAURKBRIPK1JAK2JAK3 | |
| SCHEMBL10294570 | 0.85 | AURKA (0.49) | AURKAAURKBRIPK1 | |
| SCHEMBL10312130 | 0.84 | IGF1R (0.60) | AURKAAURKB | |
| SCHEMBL10312214 | 0.83 | FLT3 (0.55) | AURKAAURKB | |
| SCHEMBL12455564 | 0.80 | AURKA (0.45) | AURKAAURKBRIPK1 | |
| SCHEMBL10312059 | 0.79 | AURKA (0.50) | AURKAAURKBRIPK1JAK2JAK3 | |
| SCHEMBL10312168 | 0.79 | AURKA (0.71) | AURKAAURKBRIPK1JAK2JAK3 | |
| SCHEMBL10294908 | 0.79 | AURKA (0.68) | AURKAAURKBRIPK1JAK2JAK3 | |
| SCHEMBL10312068 | 0.79 | AURKA (0.49) | AURKAAURKBRIPK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | AURKA 793/4885AURKB 584/4885RIPK1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.